Sepracor Beats Back Naysayers
Shares of Sepracor (SEPR) soared Tuesday after the company issued fourth-quarter financial results that bulldozed Wall Street's expectations and enabled the company to enjoy its first profitable year.
The Marlborough, Mass., maker of the sleep drug Lunesta and the asthma medication Xopenex issued 2006 earnings and revenue guidance that exceeded the consensus prediction among analysts.
By early afternoon, Sepracor's stock was up $7.12, or 14.7%, to $55.50 on trading that was eight times the average daily volume for the past three months. The stock rose as high as $55.89.
Sepracor reported a fourth-quarter profit of $37.2 million, or 32 cents a share, on revenue of $311.1 million. Analysts polled by Thomson First Call expected a profit of 5 cents a share on revenue of $282.9 million. For the same period last year, Sepracor lost $33.7 million, or 33 cents a share, on revenue of $131.4 million.The fourth-quarter results sent the full year into the black. Sepracor earned $4.97 million, or 4 cents a share, on revenue of $820.9 million last year. The consensus estimate called for a full-year loss of 42 cents a share on revenue of $793.7 million. "This should silence the multitude of bears," says Corey Davis of J.P. Morgan, who reaffirmed his overweight rating on the stock. Lunesta produced fourth-quarter sales of $144.9 million, and Xopenex contributed $158 million, both of which exceeded Davis's expectations. "We think there's plenty of upside here, given the recent surges in both market growth and share gains," says Davis, who doesn't own shares and whose firm has provided non-investment-banking services in the past 12 months. The bearish case is that Sepracor can't sustain the necessary growth in Lunesta prescriptions and sales while it spends heavily to promote the drug against bigger, deeper-pocketed opponents. Competitors include Sanofi-Aventis (SNY), which sells Ambien and Ambien CR, and Takeda Pharmaceuticals, the maker of Rozerem.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV